Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

“The formation of Dogwood Therapeutics last month represents a transformational expansion of our pipeline with the addition of Halneuron ®, a non-opioid, novel NaV 1.7 modulator to treat neuropathic ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

Such pain can feel like burning, stabbing, sharp and squeezing sensations, says the MS Society. MS sufferers can experience ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

A recent study found that patients’ perioperative pain experience was a better predictor of chronic postsurgical pain than acute pain intensity.

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an ...